Drug intelligence / Profile preview

IMCY-0685

Development stage: Preclinical
Lead developer: Imcyse
Modality: Peptides

Overview

IMCY-0685 is a synthetic peptide drug developed by ImCyse SA, designed to halt the progression of neuromyelitis optica (NMO) by stopping the body's immune system from attacking the central nervous system. It is part of ImCyse’s broader pipeline targeting severe, chronic autoimmune diseases where no therapeutic cures are available and existing therapies manage disease symptoms often with frequent and severe side effects. The drug leverages Imotope technology, which can be adapted for use in various diseases beyond autoimmune conditions[2][3].

Targets

MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on IMCY-0685.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMCY-0685.

Explore the full profile